Novavax announced the initiation of a phase II trial for its applicants for autonomic and influenza vaccines combined with COVID-19 (CIC). 80 years old.
“We are encouraged to start this trial given the positive effects shared earlier this year of our Phase I/II trial, the first of its kind to compare a mixed COVID-19 and influenza vaccine,” said Stanley C. Erck, president and CEO, Novavax. We believe that, like influenza, COVID-19 will also be seasonal and that there is room in the market for new opportunities to provide greater coverage against the effects of influenza, especially in the elderly, and to explore the possibility of mixing this with COVID coverage.
The randomized, observer-blind trial will compare a mixture of Novavax’s recombinant protein-based COVID-19 vaccine (NVX-CoV2373), a quadrivalent influenza vaccine candidate, and a patented saponin-based Matrix-M™ adjuvant. The objectives of the review are to compare the safety, tolerability, and immune responses to formulations of CICs and influenza vaccine candidates. The Phase II confirmatory dose trial will be conducted in two parts and aims to enroll a total of approximately 2300 participants at multiple sites in Australia. and New Zealand.
The first effects of the trial are expected in mid-2023.